# Discovery of the High-Affinity Aptamer for Candidalysin Using a Dual-Mode Colorimetric–SERS Platform

## TL;DR

Researchers developed a new biosensor to find a high-affinity aptamer for the Candida albicans toxin Candidalysin, which could lead to better treatments for candidiasis.

## Contribution

A dual-mode biosensor combining colorimetric and SERS detection was developed to screen high-affinity aptamers for Candidalysin.

## Key findings

- A specific high-affinity aptamer for Candidalysin was successfully identified.
- The dual-mode biosensor improved detection accuracy by reducing false-negative signals.
- This work offers a promising strategy for developing therapeutics against Candida infections.

## Abstract

Candida albicans poses significant health risks through its virulent peptide toxin Candidalysin. As no existing therapeutics specifically target this toxin, developing high-affinity aptamers for its efficient and safe removal is urgently needed. In response, we developed a dual-mode biosensor based on gold nanoparticles (AuNPs) and aptamers for screening high-affinity aptamers for Candidalysin. This biosensor leverages the localized surface plasmon resonance (LSPR) phenomenon and surface-enhanced Raman scattering (SERS) of AuNPs to detect changes in color and Raman signals, respectively, indicative of high-affinity aptamer for Candidalysin presence. This dual-mode capability reduces false-negative signals and enhances detection accuracy. Our findings reveal a specific aptamer with high affinity for Candidalysin, presenting a significant advancement in candidiasis treatment. This work sets the stage for the development of effective therapeutic strategies against Candida infections.